Autosomal Dominant Axonal Charcot-Marie-Tooth Disease

Other names
Types
Causes
Symptoms
Diagnostic tests
Goals of treatment in autosomal dominant axonal CMT
Drug treatments
Dietary molecular supplements
Regenerative, immunity-boosting and stem-cell-related drugs
Surgical treatments
Prevention of complications
When to see doctors
What to eat and what to avoid
Frequently asked questions (FAQs)

Autosomal dominant axonal Charcot-Marie-Tooth disease is a group of inherited nerve disorders in which the long “wires” of the nerves (axons) slowly become damaged. These nerves carry movement signals to the muscles and feeling signals from the skin, mostly in the feet, legs, hands and arms. Over time this damage causes muscle weakness, thinner muscles (atrophy), foot deformities and loss of sensation, usually starting in the feet and moving upward. Doctors place these disorders in Charcot-Marie-Tooth type 2 (CMT2), also called hereditary motor and sensory neuropathy type 2, which is mainly an axonal neuropathy rather than a myelin (insulation) problem. NCBI+2Europe PMC+2

Autosomal dominant axonal Charcot-Marie-Tooth disease (often grouped within CMT type 2, or CMT2) is a genetic disorder that damages the long “wires” (axons) of the peripheral nerves. These nerves carry movement signals from the spinal cord to the muscles and bring back sensation from the skin. In the axonal forms of CMT, the main problem is in the axon itself, not mainly in the myelin covering, so nerve signals become weak and slow.Wikipedia+1

“Autosomal dominant” means that a person can get the disease if they receive one changed (mutated) gene from either parent. Each child of an affected parent has about a 50% chance to inherit the changed gene. In axonal CMT2, weakness and wasting usually start in the feet and lower legs, later affecting the hands and forearms. People may have high-arched feet, claw toes, foot drop, balance problems, numbness and nerve pain. The disease is usually slowly progressive over many years.Muscular Dystrophy Association+2CMT Research Foundation+2

In this condition the inheritance pattern is autosomal dominant. This means one changed copy of the gene from either parent is enough to cause the disease. Many CMT2 families show this pattern, so the condition often runs strongly in families, although new (de novo) mutations can also appear in a child with no family history. JAMA Network+1

In axonal CMT the nerve conduction speed on nerve conduction studies is usually normal or only mildly slow, but the strength of the electrical signal is reduced because many axons are lost. Sural nerve biopsy and electrodiagnostic studies show clear signs of axonal degeneration with little or no primary myelin damage. This helps doctors separate axonal CMT2 from demyelinating CMT1. JAMA Network+2JAMA Network+2

Other names

This disease is known by several other medical names. It is often called Charcot-Marie-Tooth disease type 2 (CMT2) when the axonal form is autosomal dominant. Many doctors also use the older term hereditary motor and sensory neuropathy type 2 (HMSN II) for the same group of disorders. NCBI+1

Some subtypes have more specific names based on the gene or mapping location. Examples include CMT2A (MFN2-related), CMT2G, CMT2O, CMT2Q, and CMT2Z, all of which are autosomal dominant axonal neuropathies with slightly different typical ages of onset and patterns of weakness. NCBI+4NCBI+4Muscular Dystrophy Association+4

MFN2-related disease is also called MFN2-hereditary motor and sensory neuropathy (MFN2-HMSN) or Charcot-Marie-Tooth disease, axonal, autosomal dominant type 2A2A. These names highlight that the main problem is a genetic change affecting axonal function in an autosomal dominant pattern. NCBI+2NCBI+2

Types

Doctors do not think of autosomal dominant axonal CMT as a single disease but as a family of related subtypes. These subtypes are often grouped by the main gene involved or by clinical pattern. ScienceDirect+1

CMT2A (MFN2-related) – This is the most common autosomal dominant axonal CMT subtype. It is caused by changes in the MFN2 gene, which controls mitochondrial fusion. It often begins in childhood or teenage years and can be severe, with significant weakness in the lower legs and sometimes involvement of the optic nerves and vocal cords. ScienceDirect+3NCBI+3OUP Academic+3
CMT2G (LRSAM1-related) – This is an autosomal dominant axonal neuropathy mapped to chromosome 12q12–q13.3 and later linked to mutations in LRSAM1. It usually causes slowly progressive distal muscle weakness and sensory loss, mainly in the legs. Muscular Dystrophy Association
CMT2O – An autosomal dominant subtype with early childhood onset, slowly progressive distal weakness and sensory loss, and mainly lower limb involvement. Orpha
CMT2Q – A rare autosomal dominant form that usually starts in adolescence or adulthood with symmetric, slowly progressive distal weakness, reduced reflexes, high-arched feet and mild to moderate sensory loss. NCBI+1
CMT2Z – Another autosomal dominant axonal neuropathy, usually starting in the first decade of life with distal lower limb weakness and sensory loss, with later upper limb involvement. NCBI
MME-related autosomal dominant CMT2 – This form is linked to variants in the MME (membrane metalloendopeptidase) gene and shows adult-onset distal weakness, sensory loss and reduced reflexes. Orpha+2Global Genes+2
Other mapped autosomal dominant CMT2 loci – Genetic studies have identified several chromosomal regions and genes, including GARS1, NEFL, HSPB1, DNM2 and others, that produce autosomal dominant axonal neuropathies with overlapping clinical pictures. ScienceDirect+2JAMA Network+2

In day-to-day practice, clinicians often label a patient as having “autosomal dominant axonal CMT2” when the family pattern and nerve tests fit, even if the exact gene subtype has not yet been confirmed. www.elsevier.com+2Europe PMC+2

Causes

In this disease, the “causes” are mainly genetic and cellular mechanisms rather than outside lifestyle factors. Many different gene variants can damage axons in similar ways, so the clinical picture overlaps. ScienceDirect+1

MFN2 gene mutations (CMT2A) – Changes in the MFN2 gene disturb mitochondrial fusion and transport along axons. This makes long motor and sensory nerves especially vulnerable, leading to the commonest autosomal dominant CMT2 subtype. molbiolcell.org+3NCBI+3OUP Academic+3
Abnormal mitochondrial dynamics – Beyond MFN2 itself, disturbed mitochondrial fusion, fission and movement in axons leads to poor energy supply at nerve endings. Long axons then degenerate over time, causing distal weakness and sensory loss. ScienceDirect+2ScienceDirect+2
GARS1 gene variants – Mutations in the glycyl-tRNA synthetase gene (GARS1) can cause a form of CMT2 with axonal degeneration, probably by impairing protein synthesis and axonal maintenance. Wikipedia+1
NEFL gene variants – Changes in neurofilament-light chain (NEFL) affect the structural “skeleton” of axons. This makes the axon fragile and leads to distal axonal loss typical of CMT2. Wikipedia+1
HSPB1 and other small heat-shock protein genes – Mutations in HSPB1 (and related genes like HSPB8) interfere with chaperone functions and protein folding in axons, producing a dominantly inherited distal axonal neuropathy. ScienceDirect+1
DNM2 gene mutations – Dynamin 2 is important for endocytosis and membrane remodeling. Dominant mutations can lead to axonal CMT2, probably by disrupting trafficking of membrane proteins needed for axon survival. ScienceDirect
LRSAM1 gene mutations (CMT2G) – LRSAM1 encodes an E3 ubiquitin ligase. Pathogenic variants disturb protein degradation pathways in neurons, which contributes to axonal degeneration in autosomal dominant CMT2G. Muscular Dystrophy Association+1
DCAF8 gene mutations (CMT2 with giant axons) – A missense mutation in DCAF8 can cause autosomal dominant HMSN2 with giant axons, with swelling of axons and neurofilament accumulation, leading to weakness and sensory loss. Wikipedia+1
MME gene variants – Changes in MME reduce normal enzyme activity of neprilysin, leading to progressive distal axonal neuropathy in adults with autosomal dominant inheritance. Orpha+2Global Genes+2
Other autosomal dominant CMT2 loci – Clinical and genetic studies show many mapped loci where dominant variants in different genes (e.g., MPZ, GJB1 in some families) can give an axonal CMT2 phenotype. JAMA Network+2BMJ Journal of Medical Genetics+2
Autosomal dominant inheritance pattern – The core cause at family level is a dominant mutation passed from an affected parent. Each child has a 50% chance of inheriting the mutated gene and, therefore, the disease. JAMA Network+1
De novo (new) mutations – In some people the disease appears even though their parents are unaffected. This is due to a new mutation that occurred in the egg, sperm or early embryo, which then behaves as a dominant mutation in that person and their descendants. NCBI+1
Length-dependent axon vulnerability – Long axons are more sensitive to problems in energy supply and transport. Genetic changes that slightly impair these processes often show first in the longest nerves to the feet, leading to the typical “length-dependent” pattern of symptoms. Europe PMC+2ScienceDirect+2
Disrupted axonal transport – Many CMT2 genes affect microtubules, motor proteins or membrane trafficking. When axonal transport is slowed, needed proteins and organelles do not reach nerve endings, and waste products build up, causing axonal degeneration. ScienceDirect+1
Protein misfolding and aggregation – Some dominant mutations cause proteins in neurons to misfold and clump. These aggregates can poison the cell, disturb axonal structure and activate stress pathways that eventually cause nerve fiber loss. ScienceDirect+1
Impaired protein degradation systems – Ubiquitin-proteasome and autophagy systems, which clear damaged proteins, are affected in several CMT2 genes such as LRSAM1 and DCAF8. When these systems fail, toxic proteins accumulate in axons. Muscular Dystrophy Association+2Wikipedia+2
Secondary axonal damage from Schwann-cell genes – Some CMT genes are mainly expressed in Schwann cells, but the resulting myelin problems can lead secondarily to axonal degeneration. In some families the clinical picture looks like axonal CMT even when myelin involvement exists at the cellular level. Wikipedia+1
Genetic modifiers and variability – People with the same mutation can have very different disease severity. This suggests other modifier genes and background genetic factors influence how strongly the main CMT2 mutation affects axons. JAMA Network+2OUP Academic+2
Coexisting illnesses that worsen neuropathy – Conditions like diabetes, vitamin deficiencies or exposure to neurotoxic drugs do not cause the autosomal dominant mutation, but they can worsen nerve damage and make symptoms of CMT2 more severe. Mayo Clinic+2Cleveland Clinic+2
Age-related axonal degeneration – As people age, axonal repair capacity decreases. In someone carrying an autosomal dominant CMT2 mutation, this normal age-related decline adds to the genetic problem and can cause symptoms to progress over decades. JAMA Network+2JAMA Network+2

Symptoms

Symptoms usually start in the feet and legs and then move upward, sometimes later affecting the hands. The exact age of onset can range from early childhood to late adulthood, and severity varies greatly, even in the same family. NCBI+3Muscular Dystrophy Association+3Mayo Clinic+3

Distal leg muscle weakness – Many people first notice that their ankles feel weak and they tire quickly when walking. This happens because the small muscles around the ankles and feet are supplied by the longest and most vulnerable axons. Muscular Dystrophy Association+2Europe PMC+2
Foot drop – Weakness of muscles that lift the front of the foot causes the toes to drag on the ground. People may trip often and may develop a high-stepping “steppage” gait to avoid stumbling. Mayo Clinic+2Wikipedia+2
High-arched feet (pes cavus) – Imbalance between weak muscles and relatively strong others in the feet leads to high arches and clawed toes. This is a classic sign in many forms of CMT2 and can appear early in life. Genetic Diseases Center+3Mayo Clinic+3www.elsevier.com+3
Hammer toes and toe deformities – Clawing or hammering of the toes results from long-term muscle imbalance and tendon tightness. These deformities may make shoe fitting difficult and increase pressure points. Mayo Clinic+2Cleveland Clinic+2
Distal muscle wasting (atrophy) – Over time, the muscles in the feet, calves and later the hands become visibly thinner. This is because denervated muscle fibers shrink and are replaced by fat and connective tissue when nerve supply is lost. NCBI+2Cleveland Clinic+2
Weakness in hands and lower arms – As the disease progresses proximally, people may struggle with fine hand tasks like buttoning clothes, writing or opening jars. This reflects axonal loss in nerves to the intrinsic hand muscles. Muscular Dystrophy Association+2Wikipedia+2
Numbness and reduced vibration sense – Sensory axons are also affected, so people may notice numbness, reduced vibration or position sense in their feet and sometimes hands. This loss of sensation can make balance worse and increase injury risk. MedlinePlus+2Mayo Clinic+2
Tingling or burning sensations – Some patients have uncomfortable tingling, pins-and-needles or burning feelings, especially in the toes and soles. These symptoms come from damaged sensory fibers sending abnormal signals. Mayo Clinic+2Cleveland Clinic+2
Reduced or absent reflexes – Deep tendon reflexes at the ankles and sometimes knees are often reduced or absent because the reflex arc needs a healthy sensory and motor axon. This is a common finding on neurological exam. Muscular Dystrophy Association+2Europe PMC+2
Balance problems and frequent falls – Weak ankles, foot deformities and sensory loss combine to cause poor balance. People may feel unsteady in the dark or on uneven ground and may have repeated falls. Mayo Clinic+2Wikipedia+2
Fatigue with walking or standing – Because muscles are weak and nerves work less efficiently, walking or standing for long periods is tiring. Many people need to sit and rest more often or use walking aids over time. Cleveland Clinic+2JAMA Network+2
Hand clumsiness and reduced grip – Difficulty holding small objects, dropping things and slow hand movements appear when hand muscles are involved. This can interfere with daily tasks and fine work. Muscular Dystrophy Association+2Cleveland Clinic+2
Skeletal changes at knees, hips or spine – Long-standing muscle imbalance and altered gait can lead to knee hyperextension, hip problems or mild scoliosis. These are secondary changes but can add to disability. www.elsevier.com+2JAMA Network+2
Pain from joint strain or nerve damage – Many people with CMT2 have aching feet, ankle pain or neuropathic pain. Pain may come from joints and tendons working in abnormal positions or from damaged sensory nerves themselves. Mayo Clinic+2Cleveland Clinic+2
Emotional and social impact – Chronic weakness, visible deformities and mobility limits can cause low mood, anxiety and social withdrawal. Although this is not a direct nerve symptom, it is an important part of the overall disease burden. Mayo Clinic+2Practical Neurology+2

Diagnostic tests

Physical examination

A careful neurological examination is the first and most important step in diagnosing autosomal dominant axonal CMT. The doctor looks for a pattern of symptoms and signs that fits a length-dependent hereditary neuropathy. NCBI+2www.elsevier.com+2

General neurological examination – The neurologist assesses muscle strength, tone, reflexes, coordination and sensation. In autosomal dominant axonal CMT, they usually find distal weakness, reduced reflexes and glove-and-stocking sensory loss, with relatively normal proximal strength early on. NCBI+2Europe PMC+2
Gait and posture assessment – The doctor watches how the person walks, turns and stands. A high-stepping gait, foot drop and difficulty walking on heels are typical in axonal CMT2, and foot deformities like pes cavus are often visible. NCBI+3Muscular Dystrophy Association+3Mayo Clinic+3
Cranial nerve and optic examination – In some CMT2A patients, optic nerve involvement or vocal cord palsy can occur, so eye movements, vision and speech are checked. This helps identify more complex MFN2-related phenotypes. PubMed+2OUP Academic+2
Family history evaluation – Taking a three-generation family history helps confirm autosomal dominant inheritance. The pattern of affected individuals in each generation is often a key clue that points to CMT2 rather than acquired neuropathy. JAMA Network+2www.elsevier.com+2
Foot and skeletal inspection – The doctor looks closely at foot shape, toe position, calluses, and checks for scoliosis or joint deformities. These structural changes support a chronic long-standing neuropathy diagnosis. Mayo Clinic+2www.elsevier.com+2

Manual functional tests

In addition to regular examination, simple bedside manual tests help measure functional impact and track progression over time. JAMA Network+2Europe PMC+2

Manual muscle testing (MMT) – The clinician grades strength of specific muscle groups in the feet, ankles, hands and wrists by applying resistance. Patterns of distal weakness with relatively preserved proximal strength are typical in CMT2. Europe PMC+2JAMA Network+2
Heel-walking and toe-walking tests – Asking the person to walk on heels tests the muscles that lift the foot, and walking on toes tests calf strength. Difficulty with heel-walking is a sensitive sign of early foot dorsiflexor weakness in axonal CMT. Muscular Dystrophy Association+2Mayo Clinic+2
Single-leg stance and tandem gait – Standing on one leg or walking heel-to-toe in a straight line stresses balance and distal muscle control. People with CMT2 often sway or lose balance quickly because of distal weakness and sensory loss. Mayo Clinic+2Europe PMC+2
Hand dexterity tests – Simple tasks, such as buttoning a shirt, picking up coins or rapidly tapping fingers, help show how much the neuropathy has affected hand function. Slowness and clumsiness are common when the disease reaches the upper limbs. Muscular Dystrophy Association+2Wikipedia+2
Functional mobility scales – Structured scales and timed walking tests (such as a 10-meter walk) are sometimes used in clinics and research to quantify walking speed and endurance. These help follow disease progression and response to interventions. Practical Neurology+3JAMA Network+3OUP Academic+3

Laboratory and pathological tests

Lab and pathological tests help confirm the hereditary nature of the neuropathy, identify the exact gene defect and rule out other causes of axonal nerve damage. NCBI+2www.elsevier.com+2

Genetic testing panels for CMT – Next-generation sequencing panels can test many neuropathy-related genes at once, including MFN2, GARS1, NEFL, HSPB1, MME and others. A positive result showing a pathogenic autosomal dominant variant supports a specific CMT2 subtype diagnosis. BMJ Journal of Medical Genetics+3www.elsevier.com+3NCBI+3
Targeted MFN2 testing – Because MFN2 is the most common cause of autosomal dominant CMT2, some guidelines suggest testing it early in families with clear axonal CMT and male-to-male transmission. Identifying an MFN2 mutation allows accurate genetic counselling. OUP Academic+3NCBI+3JAMA Network+3
Metabolic and vitamin blood tests – Basic labs (glucose, B12, folate, thyroid function and others) are done mainly to exclude treatable acquired neuropathies that can mimic or worsen CMT2. Normal results do not rule out CMT but help narrow the diagnosis. www.elsevier.com+2Practical Neurology+2
Nerve biopsy (usually sural nerve) – In selected cases, a nerve biopsy can show axonal loss with relatively preserved myelin, supporting a diagnosis of axonal CMT2. Biopsy is used less now because genetic testing has improved, but it remains useful when genetics is inconclusive. JAMA Network+2JAMA Network+2

Electrodiagnostic tests

Electrodiagnostic studies are central in separating axonal CMT2 from demyelinating forms and from non-genetic neuropathies. Europe PMC+2ScienceDirect+2

Nerve conduction studies (NCS) – Small electrical pulses are delivered to nerves, and responses are recorded. In autosomal dominant axonal CMT, conduction velocities are usually normal or only mildly reduced, but the amplitudes of responses are low, reflecting loss of axons. Europe PMC+2JAMA Network+2
Electromyography (EMG) – A small needle electrode is inserted into muscles to record electrical activity. EMG shows signs of chronic denervation and reinnervation, such as large motor units and reduced recruitment, consistent with long-standing axonal neuropathy. Europe PMC+2JAMA Network+2
Evoked potential studies (in selected cases) – Somatosensory evoked potentials can be used when doctors suspect involvement of central pathways or want to study long sensory tracts. While not routine for all CMT2 patients, these tests can add information in complex cases. ScienceDirect+2PubMed+2

Imaging tests

Imaging does not diagnose autosomal dominant axonal CMT on its own, but it helps rule out other problems and sometimes shows patterns that support the diagnosis or document complications. www.elsevier.com+2Muscular Dystrophy Association+2

MRI of leg muscles – Muscle MRI can show characteristic patterns of fatty replacement and muscle atrophy in lower-leg muscles in different CMT2 subtypes. These patterns may correlate with specific genes and help in research and complex diagnostic cases. Muscular Dystrophy Association+2ScienceDirect+2
Peripheral nerve ultrasound or MRI neurography – High-resolution imaging of nerves can show nerve enlargement or structural changes. In axonal CMT2, nerve enlargement is often mild compared to demyelinating forms, which may help distinguish types. ScienceDirect+2Practical Neurology+2
Skeletal X-rays and foot imaging – X-rays of the feet, ankles and sometimes spine document deformities such as pes cavus, hammertoes and scoliosis. This information is important for planning orthotics or surgical correction and for tracking progression over time. Mayo Clinic+2www.elsevier.com+2

Goals of treatment in autosomal dominant axonal CMT

The main goals of treatment are:

Maintain muscle strength and joint range so that walking and hand function stay useful for as long as possible.
Correct or support deformities (for example, high-arched feet and ankle instability) using orthoses and, if needed, surgery.Dove Medical Press+1
Control neuropathic pain and muscle cramps using suitable medicines and non-drug therapies.ScienceDirect+1
Prevent complications, such as falls, joint contractures, pressure sores, and skin breakdown on the feet.PMC+1
Support emotional well-being, work and social life, because CMT is a lifelong condition that can affect confidence, mood and daily activities.Charcot-Marie-Tooth Association+1

Non-pharmacological treatments

Below are 20 key non-drug approaches. Most people will not need all of them, and the exact plan should be personalized by a rehabilitation team.

Individualized physiotherapy program
A physiotherapist designs a regular exercise plan to gently strengthen the remaining healthy muscles and keep joints flexible. This often includes stretching, light resistance training and balance activities. The purpose is to slow down loss of strength, delay contractures and keep walking as smooth and safe as possible. The main mechanism is training the muscles and nerves repeatedly so that they work more efficiently and do not stiffen from disuse.PMC+2Charcot-Marie-Tooth Association+2
Stretching to prevent contractures
Daily stretching of ankles, calves, hamstrings, fingers and wrists helps to keep joints moving through their full range. In CMT, weak muscles can shorten over time, causing fixed deformities and pain. Stretching, sometimes assisted by a therapist or with night splints, lengthens the muscles and tendons and reduces stiffness. This supports easier walking, reduces pressure spots in the foot and can delay the need for surgery.Physiopedia+1
Ankle–foot orthoses (AFOs) for foot drop
Light plastic or carbon-fiber braces (AFOs) hold the ankle in a neutral position and lift the front of the foot during walking. In axonal CMT, weakness of the muscles that raise the foot leads to tripping and high-stepping gait. AFOs mechanically support the ankle, improve foot clearance, reduce falls and reduce energy use while walking. They are one of the most helpful devices for many people with CMT.Dove Medical Press+2Pod NMD+2
Custom foot orthoses and supportive footwear
Insoles and special shoes help distribute pressure under the foot, support high arches and improve alignment of the heel and toes. Pes cavus (high-arched foot) is common in CMT and can cause pain, calluses and instability. Orthoses work by correcting or accommodating deformity and spreading load over a larger surface, which protects the skin and joints and makes walking more comfortable.Pod NMD+1
Occupational therapy for hand and daily activities
An occupational therapist teaches ways to manage fine hand weakness, such as using adapted cutlery, writing tools, fasteners and computer aids. They also advise on energy-saving methods and simple changes at home or school. The purpose is to maintain independence in dressing, writing, typing, cooking and self-care, by matching tools and techniques to the person’s remaining strength and coordination.Charcot-Marie-Tooth Association+1
Balance and gait training
Special exercises challenge standing balance, walking on different surfaces and turning safely. Axonal CMT often damages position sense in the feet, making balance harder. Training repeatedly exposes the person to safe balance challenges so that vision, inner-ear and remaining sensory input are used more effectively, lowering the risk of falls and injuries.CMT Research Foundation+2PMC+2
Aquatic (water-based) therapy
Exercise in a warm pool reduces the weight on weak legs and supports the body while moving. This allows people to practice walking, stretching and strengthening with less pain and less fear of falling. The water also provides gentle resistance that trains muscles. The purpose is to keep fitness and confidence high, especially when land-based exercise is difficult.PMC+1
Low-impact aerobic exercise
Activities such as stationary cycling, swimming or gentle walking help maintain heart and lung fitness, weight control and general health. In CMT, people may avoid activity because of fatigue or fear, which can lead to further weakness (“deconditioning”). Aerobic exercise, adjusted to individual ability, improves endurance and mood and may reduce fatigue by training the whole body to use oxygen more efficiently.PMC+1
Strength training of preserved muscles
Light resistance exercises for muscles that still have useful strength (for example, hip and core muscles) can improve stability and help compensate for weaker distal muscles. The goal is not heavy body-building but careful, supervised strengthening to improve function. The mechanism is muscle hypertrophy and better recruitment of remaining motor units, which supports posture and walking.Physiopedia+1
Pain-focused physiotherapy and manual therapy
Some therapists use gentle joint mobilization, soft tissue massage and modalities such as heat or TENS units to reduce musculoskeletal pain around weak joints. While these methods do not repair nerves, they can relax tight muscles, reduce secondary back or hip pain from abnormal gait and make it easier to stay active, which indirectly supports nerve health and mobility.PMC+1
Podiatry care and skin protection
Regular foot checks by a podiatrist help identify calluses, pressure points, ingrown nails and early ulcers. Because sensation may be reduced, people might not feel minor injuries. Podiatrists trim nails safely, advise on footwear and treat small lesions early. This prevents infections, deep ulcers and, in extreme cases, serious bone or joint problems.ScienceDirect+1
Night splints and positioning devices
Night splints can hold ankles or knees in a stretched position while sleeping to prevent contractures. Wrist or finger splints may also be used. By keeping joints in a neutral or slightly stretched position for hours, they counteract the natural tendency of weak muscles to shorten, helping maintain range of motion and more normal walking mechanics during the day.Pod NMD+1
Walking aids (cane, crutches, walker)
If balance is poor or leg weakness is significant, devices such as a cane or walker provide extra points of support. This spreads body weight and gives the brain more sensory feedback from the hands, making balance easier. Their main purpose is safety: reducing falls, fractures and fear of movement so people feel confident leaving the house and staying socially engaged.ScienceDirect+1
Home and school/work adaptations
Simple changes, such as removing loose rugs, improving lighting, installing grab bars, using ramps, or adjusting desk height, can make daily life safer and less tiring. These modifications do not change the disease but reduce physical barriers. The mechanism is environmental: obstacles are removed so the person can use their remaining strength and balance more effectively and avoid injuries.Charcot-Marie-Tooth Association+1
Psychological support and cognitive-behavioural therapy (CBT)
Living with a chronic, inherited disease can cause anxiety, low mood and worry about the future or family. Talking therapies, especially CBT, help people manage negative thoughts, develop coping skills and plan realistic goals. Managing stress and mood can also indirectly reduce pain perception and fatigue, improving overall quality of life.ScienceDirect+1
Patient education and self-management training
Clear information about the disease, its course, safe activities, foot care and warning signs empowers the person and family. Education explains why regular exercise, orthoses and skin checks are important. Understanding the condition reduces fear of movement and helps patients take part in shared decision-making with clinicians, which is linked to better adherence and outcomes.Charcot-Marie-Tooth Association+1
Genetic counselling
A genetic counsellor explains how autosomal dominant inheritance works, the chance of passing the condition to children, and options such as testing of relatives or reproductive planning. The purpose is not to tell people what to do, but to give them clear, unbiased information so they can make personal decisions. This can reduce guilt and confusion within families.MedlinePlus+1
Support groups and peer networks
Charcot-Marie-Tooth associations and online communities connect people with others facing similar challenges. Sharing experiences, practical tips and emotional support can reduce feelings of isolation. Peer information about devices, therapists and everyday adaptations often complements professional advice and helps people feel more hopeful about long-term living with CMT.Charcot-Marie-Tooth Association+1
Vocational rehabilitation and school planning
Specialists can help adapt workstations, recommend flexible schedules or identify suitable job tasks matching physical abilities. For students, individualized education plans can allow extra time, assistive technology or adapted physical education. This approach aims to keep education and employment on track, supporting financial independence and self-esteem.ScienceDirect+1
Fall-prevention programs
Targeted programs combine strength and balance exercises, home safety checks, footwear advice and education about risk situations (stairs, slippery surfaces, walking in the dark). Because axonal CMT affects proprioception and ankle strength, falls are a major concern. Structured fall-prevention reduces fractures and fear of falling and maintains community participation.PMC+2Pod NMD+2

Drug treatments

There is no drug yet approved specifically to cure or slow autosomal dominant axonal CMT. Medicines are used to treat symptoms, especially neuropathic pain, mood problems and musculoskeletal discomfort. Many drugs listed below are FDA-approved for other neuropathic pain conditions (like postherpetic neuralgia or diabetic neuropathy) and are used off-label in CMT when pain is similar. Never start, stop or change these medicines without a doctor.MDPI+1

I will highlight 10 key medicines with label-based evidence for neuropathic pain plus several commonly used supportive drugs.

Gabapentin
Gabapentin is an anti-seizure medicine widely used for neuropathic pain. FDA labels show approval for postherpetic neuralgia in adults, with typical adult dosing titrated from 300 mg once daily to 900–1800 mg/day in divided doses, depending on response and kidney function.FDA Access Data+2FDA Access Data+2 In CMT, doctors may use gabapentin off-label to reduce burning, tingling or shooting pains from damaged axons. It works by binding to calcium channels in nerve cells and reducing release of excitatory neurotransmitters, which calms overactive pain pathways. Common side effects include dizziness, sleepiness, swelling of legs and weight gain; abrupt stopping can worsen symptoms, so tapering is needed.
Pregabalin
Pregabalin is chemically related to gabapentin and is FDA-approved for neuropathic pain from diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, fibromyalgia and as add-on therapy for partial seizures.DrugBank+4FDA Access Data+4FDA Access Data+4 Label dosing for neuropathic pain in adults usually starts around 150 mg/day in divided doses and may increase to 300–600 mg/day depending on indication and tolerance. In axonal CMT, it is used off-label to ease constant burning or electric-shock pains. It reduces calcium influx in nerve terminals, lowering the release of pain-signalling chemicals. Side effects can include dizziness, drowsiness, blurred vision, weight gain, and ankle swelling; there is also a risk of dependence and withdrawal if stopped suddenly.
Duloxetine
Duloxetine is a serotonin–norepinephrine reuptake inhibitor (SNRI) antidepressant that is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain.FDA Access Data+3FDA Access Data+3FDA Access Data+3 The usual adult dose for diabetic neuropathy is 60 mg once daily; higher doses do not improve pain but increase side effects. In axonal CMT, duloxetine may be chosen when a person has both neuropathic pain and depression or anxiety. It increases serotonin and norepinephrine in the spinal cord, which strengthens descending inhibitory pain pathways. Side effects include nausea, dry mouth, sleepiness or insomnia, sweating and, rarely, liver problems or blood pressure changes.
Tricyclic antidepressants (e.g., amitriptyline, nortriptyline)
These older antidepressants are widely used for neuropathic pain even though not specifically approved for CMT. Low bedtime doses are often used (for example, 10–25 mg at night, adjusted by a doctor). They block reuptake of serotonin and norepinephrine and also act on sodium and other channels, reducing pain signal transmission. They can be very effective but may cause dry mouth, constipation, blurred vision, weight gain and drowsiness, and in high doses can affect heart rhythm, so ECG and careful dosing are important.NCBI+1
Topical lidocaine patches
Lidocaine 5% patches are FDA-approved for postherpetic neuralgia and sometimes used for localized neuropathic pain in other conditions. They are applied to painful skin areas for up to 12 hours in 24 hours, following the label. Lidocaine blocks sodium channels in the nerve endings in the skin, reducing ectopic firing without major systemic effects. In axonal CMT, they may help focal burning areas on the feet. Skin irritation is the most common side effect.NCBI+1
Capsaicin topical preparations (low- or high-strength)
Capsaicin cream or patch activates TRPV1 receptors on pain fibres, causing an initial burning sensation followed by long-lasting desensitization of the nerve ending. High-dose capsaicin patches are approved for some neuropathic pain syndromes; creams are available over-the-counter in many places. In CMT, capsaicin may reduce localized burning pain, but people with very low sensation must be careful to avoid burns. Side effects include local stinging, redness and rarely blistering; use should be supervised in neuropathy.NCBI+1
Simple pain relievers (paracetamol/acetaminophen)
Acetaminophen does not treat neuropathic pain directly, but it can help with secondary musculoskeletal pain from altered gait, joint strain or surgery. Typical adult dosing follows national guidelines (for example, up to 3–4 g/day in divided doses, with lower limits in liver disease). It works mainly in the central nervous system by reducing prostaglandin production. When used correctly, it is usually well tolerated; overdose can cause serious liver damage.NCBI
Non-steroidal anti-inflammatory drugs (NSAIDs)
Medicines like ibuprofen or naproxen reduce inflammation and are useful for joint, tendon or post-operative pain but are usually not very effective for pure nerve pain. They inhibit cyclo-oxygenase enzymes (COX-1 and/or COX-2), reducing prostaglandin production. They can cause stomach irritation or ulcers, kidney problems and increased bleeding risk, especially at higher doses or with long-term use, so they must be used carefully and often for short periods only.NCBI+1
Muscle relaxants for cramps (e.g., baclofen, tizanidine)
Some people with CMT experience painful muscle cramps or spastic-feeling stiffness. Medicines such as baclofen or tizanidine may be used to dampen overactive spinal reflexes and reduce cramping. They act on GABA or alpha-2 adrenergic receptors, reducing excitatory output to muscles. Side effects include sleepiness, dizziness, weakness and, in baclofen, withdrawal symptoms if stopped abruptly. These drugs are usually considered only when cramps are severe and non-drug measures have failed.NCBI+1
Short-term opioid or tramadol use in selected cases
In some people, severe mixed neuropathic and musculoskeletal pain may briefly require tramadol or other opioid-type medicines, usually under specialist supervision. Tramadol acts on opioid receptors and also inhibits serotonin and norepinephrine reuptake. While it can reduce pain, it carries risks of dependence, tolerance, constipation, drowsiness, breathing depression and dangerous interactions with other drugs. Because CMT is chronic, long-term opioids are generally avoided; guidelines recommend focusing on non-opioid strategies whenever possible.NCBI+1

(Other medicines such as SSRIs for depression, sleep aids, or drugs for associated conditions may also be part of the plan, but they are chosen based on the individual’s overall health. All dosing must follow label information and the treating doctor’s instructions.)

Dietary molecular supplements

There are no supplements proven to cure or stop autosomal dominant axonal CMT, but some nutrients are studied in general nerve health or other neuropathies. Evidence is often limited and sometimes mixed, so these should always be discussed with a doctor to avoid interactions or overdose.NCBI+1

Vitamin B12 (cobalamin)
Vitamin B12 is essential for myelin formation and normal nerve function. Deficiency can cause a separate neuropathy, so levels are often checked in people with nerve symptoms. When low, replacement by tablets or injections can improve nerve conduction. The “dose” depends on the level and route (for example, high-dose oral daily or periodic injections), as decided by a clinician. The mechanism is correction of deficiency and support of DNA synthesis and myelin repair.
Vitamin B1 (thiamine) and B6 (pyridoxine) in balanced doses
Thiamine and pyridoxine are important in energy production and neurotransmitter metabolism. Severe deficiencies can cause neuropathies. Balanced B-complex supplements may be used when diet is poor or labs show low levels. However, excessive B6 over time can itself cause nerve damage, so doses must remain within safe limits set by guidelines. The purpose is to correct deficiency, not to “super-boost” nerves.
Alpha-lipoic acid
Alpha-lipoic acid is an antioxidant used in some countries for diabetic neuropathy. Studies suggest it may reduce oxidative stress and improve microcirculation in nerves. Typical oral doses in diabetic neuropathy trials have been around 600 mg/day, but safety and benefit in CMT specifically are not well proven. It may cause nausea or skin rash and can affect blood sugar, so medical supervision is needed.PMC
Acetyl-L-carnitine
Acetyl-L-carnitine participates in mitochondrial energy metabolism and fatty acid transport. Small studies in other neuropathies suggest potential improvements in pain and nerve fibre regeneration. Proposed doses often range around 500–1000 mg 2–3 times per day, but exact regimens must be personalised. Mechanistically, it may support mitochondrial function and nerve repair processes. Gastrointestinal upset is a possible side effect.
Omega-3 fatty acids (EPA/DHA)
Omega-3 fats from fish oil or algae have anti-inflammatory effects and may support cell membrane health. While they do not fix the genetic cause of CMT, they can contribute to general cardiovascular health and may slightly reduce inflammation around nerves and joints. Doses often range from about 500–1000 mg EPA+DHA daily, keeping in mind that higher doses can increase bleeding risk, especially with anticoagulants.
Vitamin D
Vitamin D is crucial for bone health and may have roles in immune and muscle function. Low vitamin D is common in people with limited outdoor activity. Correcting deficiency using doses guided by blood tests can strengthen bones, which is important in people at risk of falls. Mechanism: regulation of calcium and phosphate balance, supporting muscle contraction and bone mineralization. Excess vitamin D can cause high calcium, so testing and monitoring are essential.
Coenzyme Q10 (CoQ10)
CoQ10 is part of the mitochondrial electron transport chain, involved in energy production. In some mitochondrial disorders, CoQ10 supplementation can help; in CMT, evidence is limited but some clinicians may consider it for fatigue. Typical doses in other conditions are around 100–300 mg/day. It may improve cellular energy and act as an antioxidant. Side effects are usually mild (stomach upset) but interactions with blood thinners are possible.
Magnesium
Magnesium supports normal muscle and nerve function and may help muscle cramps if levels are low. Supplementation is usually in the range of 200–400 mg elemental magnesium daily, adjusted for kidney function and other medications. Its mechanism includes stabilizing nerve membranes and supporting muscle relaxation. Too much magnesium can cause diarrhea and, in kidney disease, dangerous accumulation.
Curcumin (from turmeric)
Curcumin has antioxidant and anti-inflammatory properties studied in many conditions. In theory, it may reduce inflammatory stress around nerves, although there is no strong direct evidence in CMT. Absorption is low, so formulations with enhanced bioavailability are often used. Doses and safety need medical review, especially for people with gallbladder disease or those taking anticoagulants.
N-acetylcysteine (NAC)
NAC is a precursor of glutathione, a key antioxidant. It is used in some settings to protect the liver or as a mucolytic. Experimental work suggests it may protect nerve cells from oxidative damage, but robust clinical trial evidence in CMT is lacking. Doses in other indications vary widely; side effects include nausea and rare allergic reactions. It should only be used under supervision.NCBI+1

Regenerative, immunity-boosting and stem-cell-related drugs

For autosomal dominant axonal CMT, there are currently no FDA-approved stem cell drugs, gene therapies or “immunity booster” medicines specifically proven to regenerate damaged axons. Research is active, but treatments remain experimental.PubMed+2Semantic Scholar+2

Six important research directions are:

Gene replacement or gene silencing therapies – aiming to correct or reduce the effect of the mutant gene in specific CMT2 subtypes; still in pre-clinical or early trial stages.
Neurotrophic growth factors – molecules that support nerve survival and regeneration; delivery and side effects remain challenging.
Small molecules targeting mitochondrial function – especially where CMT genes affect mitochondria (for example MFN2-related axonal CMT); trials are ongoing.PubMed+1
Remyelinating or axon-stabilizing agents – designed to improve nerve conduction or protect axons from degeneration.
Induced pluripotent stem cell (iPSC)-derived nerve or Schwann cells – used mainly in the lab and in early research to model disease and test drugs.
Mesenchymal stem cell therapies – being studied for various neurological conditions, but not established or approved for CMT.

Because these approaches are experimental, there are no standard doses or routine clinical protocols, and they should only be accessed through properly regulated clinical trials, not in unregulated “stem cell clinics,” which can be risky and expensive.Semantic Scholar+1

Surgical treatments

Surgery in axonal CMT does not cure the disease but can correct deformities and improve function or reduce pain. Candidates are chosen carefully by orthopedic surgeons experienced in neuromuscular foot problems.Pod NMD+1

Foot deformity correction (osteotomy)
Surgeons may cut and realign bones of the foot to correct high arches, heel varus or other deformities. By reshaping the bone, weight-bearing is redistributed and the foot becomes more stable and plantigrade (flat on the ground). This helps with brace fitting, improves walking and reduces pain and skin pressure.
Tendon transfer procedures
In tendon transfer, a tendon from a relatively strong muscle (for example, one that still lifts the ankle) is moved to assist a weaker function, such as lifting the front of the foot. The goal is to restore better balance of muscle forces around the ankle and toes. This can reduce foot drop and improve clearance during walking, sometimes reducing dependence on AFOs.
Achilles tendon lengthening
If the calf–Achilles complex becomes very tight, the ankle may be stuck in a downward-pointing position (equinus). Lengthening the Achilles tendon allows the ankle to move closer to neutral, improving heel contact during walking and making it easier to use orthoses. It can also relieve pain from constant toe-walking.
Ankle fusion (arthrodesis)
In severe deformity or instability where joints are rigid and painful, surgeons may fuse (stiffen) the ankle or subtalar joint in a corrected position. Although movement at that joint is lost, overall walking can become more stable and less painful. This is usually considered when other surgeries or orthoses cannot provide enough support.
Spinal surgery for severe scoliosis
Some people with CMT develop significant curvature of the spine. When curves are large, progressive or affecting breathing, spinal fusion or other corrective procedures may be recommended. The purpose is to prevent further deformity, protect lung function and reduce pain. Decision-making involves weighing surgical risks against potential long-term benefits.Pod NMD+1

Prevention of complications

We cannot yet prevent the genetic cause of autosomal dominant axonal CMT, but we can prevent or reduce many complications:

Avoid nerve-toxic medicines (for example, some chemotherapy agents like vincristine) whenever possible, as they can worsen neuropathy; any such decision must be made by specialists balancing cancer and nerve risks.Wikipedia+1
Protect the feet with well-fitting shoes, daily inspections and prompt treatment of blisters or cuts to avoid ulcers and infections.ScienceDirect+1
Maintain regular physiotherapy and stretching to prevent contractures and maintain mobility.
Use orthoses and walking aids early rather than waiting for repeated falls, to reduce injuries and fractures.Dove Medical Press+1
Keep body weight in a healthy range, as extra weight increases stress on weak feet and joints and raises surgical and cardiovascular risks.
Stop smoking and limit alcohol, because both can harm nerves and blood supply and worsen neuropathy.NCBI
Control other medical conditions such as diabetes, thyroid disease or vitamin deficiencies that can add extra nerve damage.NCBI+1
Ensure up-to-date vaccinations, especially against flu and pneumonia if mobility or lung function is reduced, to avoid infections that could lead to long periods of bed rest.
Plan safe work, sport and hobby activities, choosing low-impact options and using protective equipment to lower the risk of ankle sprains and falls.
Attend regular follow-up with neurology and rehabilitation teams so changes can be picked up early and new treatments offered as research progresses.ScienceDirect+1

When to see doctors

You should be under regular care of a neurologist, physiotherapist and, when needed, orthopaedic and rehabilitation specialists. Seek urgent or early medical review if:

There is sudden or rapidly worsening weakness, especially if you lose the ability to walk, climb stairs or use your hands much faster than usual.
You notice new breathing problems, such as shortness of breath at rest, needing extra pillows to sleep or frequent chest infections.CMT Research Foundation+1
You develop new swallowing difficulties, choking, or significant weight loss.
You have severe, uncontrolled pain that does not respond to usual medicines or keeps you from sleeping.NCBI+1
You find ulcers, deep cracks or infections on your feet or ankles, especially if you have reduced sensation.ScienceDirect+1
There are major mood changes, such as persistent sadness, loss of interest, thoughts of hopelessness or strong anxiety about the future; these deserve prompt support and treatment.
You are considering pregnancy, major surgery or a new intense sport or job and want to understand risks and adaptations.

Early review allows doctors to rule out other superimposed problems (like compression neuropathies or inflammatory conditions), adjust braces or medicines and provide extra support.MDPI+1

What to eat and what to avoid

Diet cannot change the gene defect, but good nutrition supports overall nerve and muscle health, weight control and bone strength.

Eat a balanced, whole-food diet rich in vegetables, fruits, whole grains, lean proteins and healthy fats to provide vitamins, minerals and antioxidants that support general health and recovery from exercise or surgery.
Include sources of B-vitamins such as whole grains, eggs, dairy, lean meats, legumes and green leafy vegetables, unless a specific medical diet says otherwise. These nutrients help energy production and nerve function.NCBI+1
Ensure enough calcium and vitamin D through dairy or fortified alternatives, small fish with bones and safe sun exposure or supplements if advised, to protect bones in people at risk of falls.
Choose healthy fats like olive oil, nuts, seeds and oily fish (if allowed), which provide omega-3 fatty acids and support cardiovascular health.
Stay well hydrated with water and limit sugary drinks, which add empty calories and worsen weight gain.

Foods and patterns to limit or avoid:

Avoid very high-sugar diets, as they worsen weight and can increase risk of diabetes, which adds extra neuropathy risk.NCBI+1
Limit highly processed foods high in trans fats and salt, which increase heart and blood-pressure risks and do not provide good nutrients.
Avoid heavy alcohol intake, because alcohol itself can damage nerves and will add to existing neuropathy. Even moderate use should be discussed with a clinician.NCBI
Be cautious with unregulated “mega-dose” supplements or herbal products that promise nerve regeneration without evidence; they may interact with medicines or be harmful to the liver or kidneys.
Follow any special diet required for other conditions (for example, diabetes, kidney disease or coeliac disease), as controlling these illnesses also protects the nerves.

Frequently asked questions (FAQs)

Is autosomal dominant axonal CMT the same as CMT2?
Autosomal dominant axonal CMT is usually grouped within CMT type 2 (CMT2), which is defined by primary axon damage and often autosomal dominant inheritance. There are many genetic subtypes (such as CMT2A, 2W, 2CC, 2Y) with overlapping features. Clinical management is broadly similar across axonal subtypes, although specific gene-targeted therapies may emerge in the future.Genetic Diseases Center+3Muscular Dystrophy Association+3NCBI+3
How fast does this disease progress?
Most axonal CMT2 forms progress slowly over years. Weakness and wasting usually start in the feet and lower legs in childhood or early adulthood and gradually move up the legs and later to the hands. Many people remain able to walk, especially with braces or surgery; a smaller number may need wheelchairs. The exact course varies greatly even within one family.CMT Research Foundation+2Genetic Diseases Center+2
Can this condition be cured now?
At present, there is no medicine or operation that removes the gene mutation or fully reverses nerve damage in CMT. Treatment focuses on preserving function, preventing complications and relieving symptoms. Rehabilitation, orthoses and surgery are currently the main evidence-based tools, while gene and stem-cell therapies remain experimental.ScienceDirect+2MDPI+2
Will exercise make my nerves worse?
Well-planned, low- to moderate-intensity exercise supervised by a physiotherapist is considered safe and helpful for most people with CMT. The aim is to avoid over-fatigue of very weak muscles but to keep stronger muscles and the heart–lung system in good shape. Sudden, very intense or high-impact exercise without guidance may cause injuries, so programs should be tailored individually.PMC+2Physiopedia+2
Is it safe to have children if I have autosomal dominant axonal CMT?
From a disease point of view, adults with CMT can often have children, but each child has about a 50% chance to inherit the mutation in autosomal dominant forms. Genetic counselling can explain options such as prenatal or pre-implantation genetic testing, and also discuss pregnancy-related issues like weight gain, falls, or anaesthetic planning. The final decision is personal and should be informed, not rushed.MedlinePlus+1
Will I need a wheelchair?
Some people use a wheelchair only for long distances or when tired; others may need one full-time if leg weakness and contractures become severe. Early use of physiotherapy, orthoses and corrective foot surgery can delay or reduce the need for a wheelchair, but there is no exact prediction for any one person. Mobility aids should be seen as tools for independence, not as a failure.Dove Medical Press+1
Are there special considerations for surgery or anaesthesia?
People with CMT may be more sensitive to certain muscle-relaxant drugs and positioning injuries during surgery. Anaesthetists should be told about the diagnosis, and careful monitoring of nerves and breathing is important. Post-operative rehabilitation and protection of weak limbs are also key. Pre-operative visits allow the team to plan safely.Semantic Scholar+1
Does CMT affect life expectancy?
For most people with CMT, life expectancy is near normal. Serious complications can arise from falls, severe scoliosis with lung problems or very advanced weakness, but these are not universal. Good medical care, prevention of complications and healthy lifestyle choices can help people live long and active lives.Wikipedia+1
Can diet alone treat my neuropathy?
No diet has been proven to cure CMT. However, a healthy diet supports bones, muscles and overall energy and can prevent additional problems like diabetes or obesity that would further harm nerves. Correcting specific deficiencies such as vitamin B12 or vitamin D is important, but “miracle” diets or extreme restrictions are not recommended.NCBI+1
Should I take every supplement that claims to help nerves?
No. Many supplements are marketed aggressively with limited or no scientific evidence, and some can interact with medicines or be harmful in high doses. It is better to focus on correcting proven deficiencies and use other supplements only after discussing with your neurologist, who can balance potential benefits and risks.NCBI+1
Can CMT be confused with other diseases?
Yes. Other neuropathies (such as diabetic, toxic, immune-mediated or vitamin-deficiency neuropathies) can look similar. That is why doctors often do nerve conduction studies, blood tests and sometimes genetic testing. Correct diagnosis matters because some acquired neuropathies are treatable in ways that inherited CMT is not.Wikipedia+1
Is there any benefit to early genetic testing?
For many families, confirming the genetic subtype helps with counselling, family planning and, in future, eligibility for gene-targeted therapies or clinical trials. On the other hand, some people may not want to know their genetic status, especially at a young age. Genetic counselling before and after testing is important so that people can make informed choices.PubMed+1
Are children treated differently from adults?
The basic principles (physiotherapy, orthoses, foot care) are similar, but in children there is special focus on growth, school activities and emotional support. Braces and shoes must be adjusted often, and surgical timing is chosen carefully to support growth plates. Children and teenagers may also need help dealing with feeling “different” from peers.Charcot-Marie-Tooth Association+2Pod NMD+2
How can families help a person with CMT?
Family members can support regular exercise, safe home arrangements, attendance at appointments and emotional encouragement. They can learn how to recognize signs of complications, like foot ulcers or sudden weakness, and help communicate with teachers or employers. At the same time, allowing the person to be as independent as possible is important for confidence.Charcot-Marie-Tooth Association+1
What research hope exists for the future?
Research on autosomal dominant axonal CMT is moving quickly. Scientists are identifying more genes, understanding axonal degeneration pathways and testing gene-based treatments, neuroprotective drugs and stem-cell-derived models. While no cure is available yet, the growing number of clinical trials and gene-therapy successes in other neurologic diseases give realistic hope that more specific treatments will appear in the coming decades.MDPI+3PubMed+3ScienceDirect+3

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.